Revenue
2021
2022
2023
2024
2025
Nexalin Technology, Inc. (NXL)
Price—Loading quote
Net income
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $301,647 | $168,721 | $110,748 | $1.3M | $144,065 |
| Gross profit | $240,274 | $132,128 | $85,060 | $958,145 | $122,623 |
| Research & development | $1.1M | $1.2M | $1.9M | $511,000 | $139,000 |
| Operating expenses | $8.6M | $7.9M | $5.8M | $2.8M | $6.1M |
| Operating income | −$8.4M | −$7.8M | −$5.7M | −$1.8M | −$6.0M |
| Net income | −$8.2M | −$7.6M | −$4.6M | −$1.7M | −$6.1M |
| Basic EPSper diluted share | -$0.50 | -$0.83 | -$0.63 | -$0.30 | — |
| Diluted EPSper diluted share | -$0.50 | -$0.83 | -$0.63 | -$0.30 | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 10, 2025Form 4 | OSSER LEONARD +1TenPercentOwner,Other | SellCommon Stock Warrants · derivative | 23.1K | $0.02 | $463.00 | 112.8K |
| Mar 12, 2025Form 4 | Shelton Carolyn HambySr. VP - Quality, Regulatory | BuyCommon Stock · indirect | 6.0K | $2.20 | $13.2K | 30.0K |
| Feb 4, 2025Form 4 | Owens DavidChief Medical Officer | BuyCommon stock | 1.0K | $3.10 | $3.1K | 155.8K |
| Feb 4, 2025Form 4 | Owens DavidChief Medical Officer | BuyCommon stock | 1.0K | $2.98 | $3.0K | 154.8K |
| Jan 28, 2025Form 4 | Owens DavidChief Medical Officer | BuyCommon stock | 1.5K | $2.70 | $4.1K | 153.8K |